Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Corvus Pharmaceuticals Inc (CRVS) USD0.0001

Sell:$3.54 Buy:$3.57 Change: $0.14 (4.09%)
NASDAQ:1.15%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.54
Buy:$3.57
Change: $0.14 (4.09%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.54
Buy:$3.57
Change: $0.14 (4.09%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Contact details

Address:
863 Mitten Rd Ste 102
BURLINGAME
94010-1311
United States
Telephone:
+1 (650) 9004520
Website:
www.corvuspharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CRVS
ISIN:
US2210151005
Market cap:
$98.54 million
Shares in issue:
29.33 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Richard Miller
    Chairman of the Board, President, Chief Executive Officer
  • Leiv Lea
    Chief Financial Officer
  • Daniel Hunt
    Senior Vice President and Chief Business Officer
  • William Jones
    Vice President of Pharmaceutical Development
  • Mehrdad Mobasher
    Vice President and Chief Medical Officer
  • Erik Verner
    Vice President of Chemistry Research

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.